Full Answer
Why did Tilray’s stock price jump today?
However, Tilray’s jump in stock price today is probably due to Tilray’s future guidance. According to Simon, Tilray’s current growth, combined with cannabis legalization momentum, should skyrocket the company’s revenue to $4 billion by the end of 2024.
When will Tilray reach its cost synergies goal?
After the completion of the Aphria-Tilray merger in May 2021, Tilray has achieved nearly US$76 million in cost synergies. By the end of May 2022, the company expects to reach its goal of achieving US$80 million Synergy — way ahead of schedule.
Is Tilray a buy on Germany's march toward legalization?
Tilray is obviously well positioned to take advantage of Germany's march toward legalization. But the company is still unlikely to realize any significant financial gains from this promising legal development any time soon. As a result, Tilray's stock is arguably only a strong buy for folks with a long-term investing horizon.
Why is Tilray stock going up?
Cannabis plants are pictured in a greenhouse of Tilray medical cannabis producer. Shares of Tilray traded higher on Wednesday after the Canadian cannabis company posted earnings that beat expectations but revenue that missed forecasts.
Is Tilray a Good stock to invest in?
The 2021 merger between two strong cannabis companies, Tilray (TLRY -4.47%) and Aphria, is turning out to be fruitful. Since the deal was completed, Tilray has reported impressive quarterly results. Its recent third quarter (ended Feb. 28) report had some brights spots for investors.
Will Tilray stock ever go up?
Tilray Brands Inc (NASDAQ:TLRY) The 16 analysts offering 12-month price forecasts for Tilray Brands Inc have a median target of 5.25, with a high estimate of 23.00 and a low estimate of 2.60. The median estimate represents a +59.57% increase from the last price of 3.29.
Is Tilray a buy sell or hold?
Tilray has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.
Will Tilray bounce back?
As the cannabis market recovers, Tilray should therefore be one of the first to rebound based on its diversified portfolio — all while holding onto the top spot in the Canadian market. The post Why Tilray Will Be the First Cannabis Stock to Bounce Back appeared first on The Motley Fool Canada.
Should I sell my Tilray stock?
(TLRY-Q) Rating. Stockchase rating for Tilray Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
Will Tilray pay dividends?
TLRY Tilray Brands, Inc. TLRY does not currently pay a dividend.
What is the target price for TLRY?
Stock Price Target TLRYHigh$23.00Median$5.25Low$2.60Average$7.22Current Price$3.30
Is Tilray buying HEXO?
Tilray Brands Inc. TLRY, -10.57% rose 1.3% in premarket trades on Tuesday after the cannabis company said it crafted more favorable terms in its deal to acquire Hexo Corp. HEXO, -5.00% .
Is Tilray stock undervalued?
While there's an argument that Tilray's stock is undervalued, I'm more inclined to the counterargument that investors may simply no longer be willing to pay the high multiples they used to for pot stocks. For the expected level of growth, the market appears to attribute a premium to Canopy Growth.
Is NIO a buy or sell?
The NIO stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Why is TLRY stock dropping?
Tilray shares down after cannabis producer posts wider net loss.
The marijuana leader wants to build a global consumer goods empire
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Tilray ( NASDAQ:TLRY) jumped 13.6% on Monday after the cannabis company reported a significant improvement in its operational and financial results.
So what
Tilray's net revenue climbed 20% year over year to $155 million in its fiscal 2022 second quarter, which ended on Nov. 30. The gains were driven in part by the company's expansion into alcohol and hemp-based wellness products.
Now what
The cannabis leader also announced its plans to change its name to Tilray Brands, to reflect its desire to become a "global consumer packaged goods powerhouse." The company intends to bolster its Manitoba Harvest hemp and CBD (cannabidiol) wellness division and SweetWater craft brewing brand via distribution and innovation investments.
What is a multi state operator?
In the U.S., multi-state operators , or MSOs, dominate the cannabis markets. They are profitable and do not spread themselves thin. For example, Green Thumb, a pioneer of the MSO model, has a presence in 14 states.
Where is Tilray made?
In Portugal, Tilray has a high-quality production facility. It also has a cultivation and production facility in Germany.
Did Tilray merge with Aphria?
The Wall Street Journal reported last week that Tilray had made a plan to expand to the U.S.,. That’s nothing new. Last year, it merged with Aphria in an effort to facilitate an aggressive expansion into the country.
Will Tilray overpay for MSOs?
The value of their shares will get diluted as the company buys MSOs. Chances are high that Tilray will overpay for a U.S. cannabis operator. Investors can consider buying the shares of MSOs, in an effort to guess which companies Tilray may acquire.
Is Tilray a disappointment?
Cannabis company Tilray (NASDAQ: TLRY) is undeniably a disappointment. Meme traders sent TLRY stock to an unsustainable high of $67 in February. Since then, the stock has fallen steadily.
Does Chris Lau have any positions in the securities mentioned in this article?
On the date of publication, Chris Lau did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
